Absence of significant effects by levamisole on circulating neutrophil levels in normal mice treated with 5-FU
| Autor: | Fisher Mc, Kimball Es |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Pharmacology
medicine.medical_specialty Chemotherapy Neutropenia medicine.drug_class business.industry Ratón medicine.medical_treatment Levamisole medicine.disease Immunostimulant Mice Endocrinology Internal medicine Toxicity medicine Absolute neutrophil count Animals Platelet Fluorouracil business Bone Marrow Diseases medicine.drug |
| Zdroj: | Immunopharmacology. 27:137-143 |
| ISSN: | 0162-3109 |
| DOI: | 10.1016/0162-3109(94)90048-5 |
| Popis: | When B6C3F1 mice were given a single intravenous (i.v.) injection of 150 mg/kg 5-fluorouracil (5-FU) their levels of circulating neutrophils plummeted, reaching a nadir at 6 to 7 days postdosing and then gradually increasing to normal and above-normal levels. Neutropenia (actual neutrophil count (ANC) below 100 ANC/microliters) extended until 8.7 +/- 0.2 days after 5-FU injection. When these mice were also given levamisole (2.5 mg/kg, po) on days 0-2 the mean time to ANC recovery greater than 100/microliters was 7.7 +/- 0.3 days, (p0.05 vs. controls), while IL-1 (2 micrograms/day, ip) positive controls yielded a mean time to100 ANC of 6.5 +/- 0.2 days. Although levamisole-treated mice attained normal neutrophil levels one day faster than controls did and this more rapid recovery led to their neutrophil levels being between 2- and 3-fold greater, these differences were not statistically significant. Effects were only manifested on neutrophil recoveries. There were no differences between levamisole-treated mice and controls when recovery rates for platelets, monocytes or lymphocytes were examined. These results demonstrate that levamisole has, at best, only weak myelopoietic properties against 5-FU-induced myelotoxicity in mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|